Drugs that contain Netupitant; Palonosetron Hydrochloride

1. Drug name - AKYNZEO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6297375 HELSINN HLTHCARE 4-phenyl-pyridine derivatives
Mar, 2023

(5 months from now)

US10233154 HELSINN HLTHCARE Crystalline forms of an NK-1 antagonist
Sep, 2035

(12 years from now)

US10676440 HELSINN HLTHCARE Crystalline forms of an NK-1 antagonist
Sep, 2035

(12 years from now)

US9951016 HELSINN HLTHCARE Crystalline forms of an NK-1 antagonist
Sep, 2035

(12 years from now)

US10961195 HELSINN HLTHCARE Crystalline forms of an NK-1 antagonist
Sep, 2035

(12 years from now)

CN107001275A HELSINN HLTHCARE Form Of Nk-1 Antagonist
Nov, 2019

(2 years ago)

CN1142144C HELSINN HLTHCARE 4-Phenyl-Pyridine Derivatives
Feb, 2020

(2 years ago)

CN1270959A HELSINN HLTHCARE 4-Phenyl-Pyridine Derivatives
Feb, 2020

(2 years ago)

IN215447B HELSINN HLTHCARE 4-Phenyl-Pyridine Derivatives
Feb, 2020

(2 years ago)

IN200000144I4 HELSINN HLTHCARE 4-Phenyl-Pyridine Derivatives
Feb, 2020

(2 years ago)

EP1394150A1 HELSINN HLTHCARE 4-Phenylpyridine Derivatives And Their Use As Nk-1 Receptor Antagonists
Feb, 2020

(2 years ago)

EP1394150B1 HELSINN HLTHCARE 4-Phenylpyridine Derivatives And Their Use As Nk-1 Receptor Antagonists
Feb, 2020

(2 years ago)

EP1035115B1 HELSINN HLTHCARE 4-Phenylpyridine Derivatives And Their Use As Nk-1 Receptor Antagonists
Feb, 2020

(2 years ago)

EP1035115A1 HELSINN HLTHCARE 4-Phenylpyridine Derivatives And Their Use As Nk-1 Receptor Antagonists
Feb, 2020

(2 years ago)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8951969 HELSINN HLTHCARE Compositions and methods for treating centrally mediated nausea and vomiting Nov, 2030

(8 years from now)

US9186357 HELSINN HLTHCARE Compositions and methods for treating centrally mediated nausea and vomiting Nov, 2030

(8 years from now)

US9943515 HELSINN HLTHCARE Compositions and methods for treating centrally mediated nausea and vomiting Nov, 2030

(8 years from now)

US8623826 HELSINN HLTHCARE Compositions and methods for treating centrally mediated nausea and vomiting Nov, 2030

(8 years from now)

US10828297 HELSINN HLTHCARE Compositions and methods for treating centrally mediated nausea and vomiting Dec, 2030

(8 years from now)

US9271975 HELSINN HLTHCARE Compositions and methods for treating centrally mediated nausea and vomiting Sep, 2031

(8 years from now)

Treatment: Use in combination with dexamethasone in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of cancer chemotherapy, including, but not limited to, highly emetogenic chemotherapy

Dosage: CAPSULE;ORAL

More Information on Dosage
Strength Dosage Availability
300MG;EQ 0.5MG BASE CAPSULE;ORAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.